Corium is a commercial-stage biopharmaceutical company leading the development of new transdermal healthcare products that provide clinicians with important treatment options for patients and their families.

Read more

 
May 14, 2018
Corium Reports Second Quarter Fiscal 2018 Financial Results and Corporate Highlights
MENLO PARK, Calif. , May 14, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the second…


May 5, 2018
Corium to Report Second Quarter Fiscal 2018 Financial Results on Monday, May 14, 2018
MENLO PARK, Calif. , May 08, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the second quarter ended March 31, 2018 on Monday, May 14, 2018 after the close of the U.S. financial markets. Corium will host a conference call…

OUR LEAD PRODUCT

CorplexTM Donepezil

A once-weekly treatment for Alzheimer’s disease, our lead product is a transdermal formulation of donepezil, the active ingredient in Aricept®, which is one of the most commonly prescribed treatments for the care of patients with Alzheimer’s disease. We have demonstrated sustained and controlled delivery of donepezil over a one-week period, with a pharmacokinetic (PK) profile comparable to oral Aricept taken daily for seven days. Learn more

circle_couple2